Concord Biotech (CONCORDBIO) | Stock Overview & Key Data
Concord Biotech Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: ₹2,664.00 on September 16, 2024
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Dividend Information
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Concord Biotech
CONCORDBIO
|
106.31B Mid-cap | 15.33% | 21.57% | 19.18% | 1.44% | 3.29% | -35.83% | 43.59% | 43.59% | 43.59% | 43.59% | 43.59% |
|
Biocon
BIOCON
|
566.52B Large-cap | 1.66% | -3.27% | 10.34% | 6.50% | 7.30% | 17.90% | 71.09% | 5.03% | 250.57% | 603.49% | 1,357.39% |
|
OneSource Specialty
ONESOURCE
|
202.76B Large-cap | -6.58% | -11.52% | 8.72% | 0.44% | -9.19% | -20.38% | -5.70% | -5.70% | -5.70% | -5.70% | -5.70% |
|
Blue Jet Healthcare
BLUEJET
|
69.97B Mid-cap | 11.86% | 17.17% | 41.50% | -8.00% | -4.67% | -46.26% | 31.46% | 31.46% | 31.46% | 31.46% | 31.46% |
|
Supriya Lifescience
SUPRIYA
|
51.74B Mid-cap | 3.93% | 38.73% | 66.47% | 32.20% | 28.93% | 41.71% | 283.42% | 102.02% | 102.02% | 102.02% | 102.02% |
|
Zota Health Care
ZOTA
|
39.41B Small-cap | 3.68% | 3.22% | 14.06% | -26.10% | -17.99% | 27.17% | 243.00% | 632.12% | 1,248.00% | 1,248.00% | 1,248.00% |
Ownership & Short Interest
Calculate Your Concord Biotech Investment Returns
Long-Term Investment Performance Analysis
Concord Biotech stock price in Aug 2023 was ₹942.80, A ₹1,000.00 lump sum investment in Concord Biotech made 2 years ago would be worth approximately ₹1,463.94 today, representing a positive return of 46.39%. This translates to an annualized return (CAGR) of 14.38%.
2 Years 10 Months Investment Scenario (Aug 2023 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is CONCORDBIO's 52-week high and low?
- In the last 52 weeks, Concord Biotech reached a high of ₹2,146.00 (on June 16, 2025) and a low of ₹987.00 (on April 2, 2026).
- What is the market cap and P/E ratio for CONCORDBIO?
- Curious about Concord Biotech's size and valuation? Its market capitalization stands at 106.31B. When it comes to valuation, the P/E ratio (trailing twelve months) is 34.14, and the forward P/E (looking ahead) is 26.89.
- Does CONCORDBIO pay dividends? If so, what's the yield?
- Yes, Concord Biotech is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.44%, and the company has paid an average of ₹2.92 per share annually over the past 3 years.
- Who are Concord Biotech's main competitors or similar companies to consider before investing?
When looking at Concord Biotech, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Biocon
BIOCON566.52B Healthcare Biotechnology 17.90% 71.09% OneSource Specialty
ONESOURCE202.76B Healthcare Biotechnology -20.38% -5.70% Blue Jet Healthcare
BLUEJET69.97B Healthcare Biotechnology -46.26% 31.46% Supriya Lifescience
SUPRIYA51.74B Healthcare Biotechnology 41.71% 283.42% Zota Health Care
ZOTA39.41B Healthcare Biotechnology 27.17% 243.00% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Concord Biotech Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Concord Biotech's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 20.50%, the Debt to Equity ratio from the most recent quarter is 0.09, and its Gross Profit Margin stands at 76.33%.
- What is the recent revenue and earnings growth for CONCORDBIO?
- Looking at Concord Biotech's growth, its revenue over the trailing twelve months (TTM) was INR12B. Compared to the same quarter last year (YoY), quarterly revenue grew by 13.70%, and quarterly earnings saw a YoY growth of -15.10%.
- How much of CONCORDBIO stock is held by insiders and institutions?
- Wondering who owns Concord Biotech stock? Company insiders (like executives and directors) hold about 74.26% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 13.16%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.